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with suicide genes will need procedures for therapy planning and
monitoring. Finally, new biomolecules will be developed by bioen-
gineering methods which may be used for isotope-based diagno-
sis and treatment of disease.
doi:10.1016/j.ejcsup.2006.04.021
S21. CURRENT STATUS ON MOLECULAR MARKERS AND
TARGETS IN PANCREATIC DISEASE
Christoph Michalski, Jo¨rg Kleeff, Markus W. Bu¨chler, Helmut
Friess. Department of General Surgery, Heidelberg University Hospital,
Germany.
With an overall 5-year survival rate of approximately 4%, pan-
creatic ductal adenocarcinoma is one of the most aggressive
human malignancies. Studies that aimed at the understanding
of this exceptionally aggressive behavior discovered an increas-
ing number of genetic and epigenetic alterations such as dereg-
ulated growth factor receptor/ligand systems, oncogenes, tumor
suppressors, metastasis suppressors and related signal trans-
duction pathways. Alterations of these genes and their respec-
tive proteins may occur throughout pancreatic carcinogenesis
suggesting an adenoma-carcinoma model with an increasing
number of molecular and cellular alterations. The most com-
monly mutated oncogene in pancreatic cancer is K-ras which
induces cell proliferation via MAPK signaling. On the other
hand, mutations in tumor suppressors such as p53, p16 and
Smad4 also occur frequently. Besides, there are less common
mutations in the tumor suppressor genes STK11, APC, FHIT,
DCC, ARP, BRCA2, MKK4, TbR-I and TbR-II. Epigenetic alterations
in growth promoting signaling pathways of the EGF, IGF and FGF
family as well as autocrine or paracrine effects of their respec-
tive ligands have been shown to endow a growth advantage to
pancreatic cancer cells. Concomitantly, it was shown that the
important growth inhibitory pathway mediated by TGF-beta
family members and their intracellular signal transduction mol-
ecules is lost in pancreatic cancer. Resistance to apoptotic cell
death gives cancer cells a further growth advantage with down-
regulation of pro-apoptotic factors such as bak and bcl-2 or
upregulation of anti-apoptotic bcl-XL. Furthermore, aberrant
expression of genes influencing invasion and metastasis is
observed. Among those, heparanase, matrix metalloproteinases
and galectins have been shown to mainly influence invasion
while decreased expression of the metastasis suppressor KAI1
was associated with worse survival and an increased metastatic
potential.
Identified alterations of signal transduction pathways can be
used clinically as therapeutic targets, e.g. small-molecule tyrosine
kinase inhibitors and other approaches show encouraging results
in first clinical trials.
Thus, a translational research approach will be a promising
way to slow down tumor progression and improve survival and
quality of life of pancreatic cancer patients in the future.
doi:10.1016/j.ejcsup.2006.04.022
S22. NEW KEY MARKERS AND THERAPEUTIC SUBGROUPS IN
BREAST CANCER RESULTING FROM MOLECULAR STAGING
N. Harbecka, R.E. Katesa, C. Thomssenb, M. Schmitta.
aDepartments of OB & GYN, Technical University of Munich,
Germany; bDepartments of OB & GYN, University of Halle (Saale),
Germany.
In breast cancer, tumor biological markers are urgently needed
to individualize clinical decision making, particularly in order
to avoid overtreatment in the increasing number of patients
with small tumors. Urokinase-type plasminogen activator uPA
and its inhibitor PAI-1 are the first novel markers validated at
the highest level of evidence for their prognostic and predictive
impact by a multicenter therapy trial (Chemo N0) and a large
EORTC-RBG pooled analysis. Their greatest clinical use so far is
in node-negative (N0) breast cancer where the test can be used
to avoid adjuvant chemotherapy in patients with non-aggressive
disease. In addition, in intermediate-risk patients as defined by
the St. Gallen consensus, the test can be used to identify
patients who should receive chemotherapy because their tumor
has a more aggressive biology than classical pathological factors
would otherwise lead to believe. The NNBC3 therapy trial (AGO,
GBG, and EORTC PBG), which has already recruited almost 700
patients, compares risk assessment by uPA/PAI-1 to that by
established prognostic factors and evaluates optimization of
chemotherapy (FEC vs. FEC-DOC) in high-risk N0 patients. Other
promising markers include methylation markers such as PITX2
for identification of patients with good outcome under adjuvant
endocrine therapy, microarray signatures or multi-gene scores
for risk group stratification. In addition to NNBC3, other large
international therapy trials in N0 breast cancer using gene signa-
tures for risk group stratification will soon start recruitment.
The current and future challenge is to integrate the most prom-
ising tumor biological factors into advanced decision support
algorithms.
doi:10.1016/j.ejcsup.2006.04.023
S23. DNA-METHYLATION MARKERS AND YB-1 AS INDICATORS
OF THERAPY RESPONSE IN BREAST CANCER
M. Schmitta, N. Harbecka, J. Foekensb, S. Maierc, and
the EpiBreast Group. aDepartment of OB & GYN, Technical
University of Munich, Germany; bErasmus Medical Center, Rotterdam,
The Netherlands; cEpigenomics AG, Berlin, Germany.
Intrinsic or acquired resistance to chemotherapy is responsible
for failure of current treatment regimens in breast cancer. For
instance, transcription factor YB-1 regulates expression of P-gly-
coprotein gene mdr1 which plays a major role in the development
of a multidrug-resistant tumor phenotype. High YB-1 protein
expression in tumor tissue and surrounding benign epithelial
cells is significantly associated with poor outcome in patients
who received postoperative chemotherapy, indicating clinical
drug resistance. Furthermore, in untreated patients, those with
low YB-1 protein expression are still free of disease, whereas
the 5-year relapse rate in those with elevated YB-1 is 30%.
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DNA methylation in the promoter regions of genes is a prom-
inent epigenetic gene silencing mechanism associated with resis-
tance to endocrine therapy in patients with recurrent breast
cancer. We have employed a microarray-based technology to
investigate the promoter DNA methylation status of 117 candi-
date genes in tumors of breast cancer patients who received
tamoxifen as first-line endocrine treatment for recurrent breast
cancer. Of the genes analyzed, phosphoserine aminotransferase
(PSA-T1) emerged as the strongest marker to predict progres-
sion-free survival. Among the 117 candidate genes, DNA-methyl-
ation markers associated with breast cancer patient outcome
after adjuvant endocrine therapy were also identified and vali-
dated in independent groups of patients. DNA-methylation status
of PITX2 showed the strongest correlation with disease recur-
rence. These results provide validated high-level evidence that
DNA-methylation status allows clinically relevant risk assess-
ment in tamoxifen-treated breast cancer, both in the adjuvant
and palliative setting.
doi:10.1016/j.ejcsup.2006.04.024
S24. MOLECULAR PATHOGENESIS OF PAPILLOMA VIRUS
ASSOCIATED CANCERS
Nicolas Wentzensen. Department of Applied Tumor Biology, Institute
of Pathology, University of Heidelberg, Germany.
A number of human cancers are caused by persistent infections
with high risk human papilloma viruses (HR-HPV), among them
about 100% of cervical cancers, many anogenital cancers, some
head and neck cancers, and a subset of skin cancers. HPVs
infect basal epithelial cells via microlesions and usually replicate
in differentiated superficial epithelial cells. Two HPV oncogenes,
E6 and E7, interfere with the hosts cell cycle and apoptosis reg-
ulation. Most importantly, E7 disrupts the binding of pRb and
E2F and induces continuous cell cycle activation. E6 triggers deg-
radation of p53 and thus abrogates apopotosis. Local immune
defense mechanisms lead to spontaneous clearance of HPV
infections in the majority of cases. In few infections, however,
deregulated expression of E6 and E7 in basal epithelial cells
induces major chromosomal instability and can initiate epithe-
lial transformation. Several characteristic changes have been
identified in epithelial cells transformed by HPV: Strong
p16INK4a expression was found in medium to high grade pre-
malignant lesions as well as in cervical cancer indicating the
functional inactivation of pRb. Proliferation associated markers
like ki67, telomerase, MCM5 and CDC6 are expressed at various
levels in premalignant lesions and invasive cancer. In advanced
lesions, high levels of chromosomal imbalances can be
observed, a very specific alteration is the gain of 3q. Integration
of HPV DNA into the host cell genome specifically indicates
advanced lesions with a high probability of progression and is
frequently found in cervical cancer. Several biomarkers, espe-
cially the detection of HR-HPV DNA and p16INK4a protein, are
currently being evaluated in order to improve existing cervical
cancer screening procedures.
doi:10.1016/j.ejcsup.2006.04.025
S25. DEVELOPING STRATEGIES FOR TUMOR VACCINATION
Andreas Mackensen. Department of Hematology/Oncology,
University of Regensburg, Germany.
Vaccination against cancer has had a variable history, with claims
of success often fading into disappointment. The reasons for this
include poor vaccine design, inadequate understanding of the
nature of the immune response, and a lack of objective measures
to evaluate performance. The characterization of tumor-associ-
ated antigens (TAAs) recognized by human T lymphocytes in a
MHC-restricted fashion has opened new possibilities for specific
vaccine approaches to the treatment of human cancers. Recent
findings include vaccine formulation, relevant knowledge con-
cerning mechanisms of induction of effective immunity from pre-
clinical models, and translation into clinical trials. We now have
novel vaccine strategies to activate specific attack on tumor cells
and we understand more about activation and regulation of
immunity against cancer (co-stimulation versus co-inhibition,
regulatory T cells). We also have modern assays using surrogate
markers (MHC multimer analysis, IFN-c Elispot assay) to correlate
with clinical effects. Although early clinical vaccine trials based
on synthetic peptides, proteins, ‘naked’ DNA, tumor-RNA, den-
dritic cells, and recombinant vaccinia viruses indicate that vac-
cines can induce immune responses and tumor regression in
some cancer patients, careful study design and use of standard-
ized clinical and immunological criteria are needed. Basic princi-
ples of tumor vaccination and clinical trials will be discussed.
doi:10.1016/j.ejcsup.2006.04.026
S26. TARGETING MUC1 WITH LIPOSOMAL BLP25
Martin H. Falk, Karl-Josef Kallen. Merck KGaA, Darmstadt,
Germany.
MUC1 is a mucin glycoprotein expressed by both normal cells and
a wide variety of epithelial carcinomas. Mucins expressed by can-
cer cells have abnormal glycosylation that results in shorter and
simpler carbohydrate chains as well as exposure of normally hid-
den (cryptic) epitopes on the protein backbone. These changes
result in unique antigenicity of cancer cell mucins relative to their
normal cell counterparts and make MUC1 an ideal candidate
antigen for immunotherapy.
L-BLP25 vaccine is an investigational therapeutic cancer vac-
cine being studied for the treatment of epithelial carcinomas.
L-BLP25 vaccine incorporates a synthetic lipopeptide sequence
identical to a portion of the protein backbone of MUC1. The vac-
cine is a liposomal formulation that consists of the synthetic
MUC1 lipopeptide, an immunoadjuvant [monophosphoryl lipid
A (MPL)], and three lipids: cholesterol, dimyristoyl phosphatidyl-
glycerol (DMPG) and dipalmitoyl phosphatidylcholine (DPPC).
The BLP25 lipopeptide provides the antigenic specificity for a T-
cell immune response, while the adjuvant serves to TLR4 to acti-
vate APCs. The liposomal delivery system is thought to ensure
delivery of peptide antigen and adjuvant to the exact same cell
as well as facilitate access to the intracellular antigen presenting
machinery of a cell.
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